Literature DB >> 1009099

Conversions of prostaglandin endoperoxides by glutathione-S-transferases and serum albumins.

E Christ-Hazelhof, D H Nugteren, D A Van Dorp.   

Abstract

Serum albumins of certain animal species (cow, sheep, pig) accelerate the decomposition of prostaglandin endoperoxides, with formation of large amounts of prostaglandin D. The reaction is inhibited by arachidonic acid, which suggests an interaction of the endoperoxide with the fatty acid binding sites of serum albumin. Glutathione-S-transferases, in the presence of glutathione, convert the endoperoxide into a mixture of prostaglandin F2alpha, E2 and D2. The prostaglandin D/E-ratio depends on the transferase used. The known rat liver transferases give mainly prostaglandin F2alpha and E2, but a new transferase in sheep lung was discovered which gives rise to large quantities of prostaglandin F2alpha and D2. The sheep lung transferase was purified to homogeneity. Two iso-enzymes with identical enzymic activity were obtained. The major component (transferase SL 2, an iso-enzyme of glutathione-S-transferase, EC 2.5.1.18) has a molecular weight of 45 000 and consists of two subunits. Its isoelectric point is 9,8-9.9. These properties, as well as the amino acid composition and the substrate specificity for typical transferase substrates, indicate a close resemblance to transferase B (ligandin), a major binding protein of rat liver. Although purified glutathione peroxidase from erythrocytes is very active in catalysing the reduction of the 15-hydroperoxy group of prostaglandins, it does not have any effect on the decomposition of the endoperoxide group.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1009099     DOI: 10.1016/0005-2760(76)90018-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

Review 1.  Glutathione S-transferase in humans in health and disease.

Authors:  P C Hayes; I A Bouchier; G J Beckett
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

2.  Competitive enzymatic interactions determine the relative amounts of prostaglandins E2 and D2.

Authors:  Rui Yu; Lei Xiao; Guiqing Zhao; John W Christman; Richard B van Breemen
Journal:  J Pharmacol Exp Ther       Date:  2011-08-24       Impact factor: 4.030

Review 3.  The prostanoids in hemostasis and thrombosis: a review.

Authors:  J B Smith
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

4.  Prostaglandin D2, a neuromodulator.

Authors:  T Shimizu; N Mizuno; T Amano; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Study of the two pathways for arachidonate oxygenation in blood platelets.

Authors:  C E Dutilh; E Haddeman; G H Jouvenaz; F Ten Hoor; D H Nugteren
Journal:  Lipids       Date:  1979-02       Impact factor: 1.880

6.  Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential.

Authors:  F A Fitzpatrick; D A Stringfellow
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

7.  Red blood cell glutathione peroxidase activity in multiple sclerosis.

Authors:  B Zachara; J Gromadzińska; J Czernicki; Z Maciejek; H Chmielewski
Journal:  Klin Wochenschr       Date:  1984-02-15

8.  Inhibition of pulmonary thromboxane A2 synthase activity and airway responses by CGS 13080.

Authors:  D B McNamara; J K Harrington; J A Bellan; G B Graybar; D C Underwood; P J Kadowitz
Journal:  Mol Cell Biochem       Date:  1989-01-23       Impact factor: 3.396

9.  Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium.

Authors:  W K Pollock; R A Armstrong; L J Brydon; R L Jones; D E MacIntyre
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

10.  Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.

Authors:  S Hamid; B J Whittle
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.